CA2002218A1 - Neoglycoproteines, preparation et utilisation - Google Patents

Neoglycoproteines, preparation et utilisation

Info

Publication number
CA2002218A1
CA2002218A1 CA2002218A CA2002218A CA2002218A1 CA 2002218 A1 CA2002218 A1 CA 2002218A1 CA 2002218 A CA2002218 A CA 2002218A CA 2002218 A CA2002218 A CA 2002218A CA 2002218 A1 CA2002218 A1 CA 2002218A1
Authority
CA
Canada
Prior art keywords
neoglycoproteins
preparation
monosialolactose
disialolactose
hsa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2002218A
Other languages
English (en)
Other versions
CA2002218C (fr
Inventor
Herbert Wiegand
Silke Bosslet
Klaus Bosslet
Hans H. Sedlacek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Publication of CA2002218A1 publication Critical patent/CA2002218A1/fr
Application granted granted Critical
Publication of CA2002218C publication Critical patent/CA2002218C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001169Tumor associated carbohydrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • G01N33/532Production of labelled immunochemicals
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6081Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002002218A 1988-11-05 1989-11-03 Neoglycoproteines, preparation et utilisation Expired - Fee Related CA2002218C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3837623A DE3837623A1 (de) 1988-11-05 1988-11-05 Neoglykoproteine, ihre herstellung und verwendung
DEP3837623.7 1988-11-05

Publications (2)

Publication Number Publication Date
CA2002218A1 true CA2002218A1 (fr) 1990-05-05
CA2002218C CA2002218C (fr) 2000-08-08

Family

ID=6366580

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002002218A Expired - Fee Related CA2002218C (fr) 1988-11-05 1989-11-03 Neoglycoproteines, preparation et utilisation

Country Status (12)

Country Link
EP (1) EP0368131B1 (fr)
JP (1) JP2838147B2 (fr)
KR (1) KR0162635B1 (fr)
AT (1) ATE142229T1 (fr)
AU (1) AU630634B2 (fr)
CA (1) CA2002218C (fr)
DE (2) DE3837623A1 (fr)
DK (1) DK549589A (fr)
ES (1) ES2093612T3 (fr)
GR (1) GR3021111T3 (fr)
IE (1) IE76312B1 (fr)
PT (1) PT92187B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008203A (en) * 1995-07-14 1999-12-28 Glycotech Corp. Methods for treatment of EGF receptor associated cancers

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3840044A1 (de) * 1988-11-27 1990-06-07 Behringwerke Ag Glykosphingolipide mit kopplungsfaehiger gruppe im sphingoidanteil, ihre herstellung und verwendung
EP0646377A1 (fr) * 1993-10-01 1995-04-05 LUANFARMA S.r.l. Extraits de tumeurs exemptes de cellules conjuguées à l'albumine, compositions antigéniques les comprenant, anticorps correspondants, et applications
US5612030A (en) 1995-01-17 1997-03-18 University Of Kentucky Research Foundation Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US5977316A (en) * 1995-01-17 1999-11-02 The Board Of Trustees Of The University Of Kentucky Monoclonal antibody 1A7 and related polypeptides
US5935821A (en) 1995-01-17 1999-08-10 Board Of Trustees Of The University Of Kentucky Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4557931A (en) * 1982-12-02 1985-12-10 Regents Of The University Of California Antigenic compositions and methods for using same
DE3840044A1 (de) * 1988-11-27 1990-06-07 Behringwerke Ag Glykosphingolipide mit kopplungsfaehiger gruppe im sphingoidanteil, ihre herstellung und verwendung

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008203A (en) * 1995-07-14 1999-12-28 Glycotech Corp. Methods for treatment of EGF receptor associated cancers
US6281202B1 (en) 1995-07-14 2001-08-28 Glycotech Corp. Pharmaceutical compositions for treatment of EGF receptor associated cancers

Also Published As

Publication number Publication date
EP0368131A2 (fr) 1990-05-16
ES2093612T3 (es) 1997-01-01
DE3837623A1 (de) 1990-05-10
PT92187A (pt) 1990-05-31
DE58909720D1 (de) 1996-10-10
AU630634B2 (en) 1992-11-05
IE893548L (en) 1990-05-05
DK549589A (da) 1990-05-06
GR3021111T3 (en) 1996-12-31
KR900007429A (ko) 1990-06-01
KR0162635B1 (ko) 1998-11-16
ATE142229T1 (de) 1996-09-15
AU4436889A (en) 1990-05-10
DK549589D0 (da) 1989-11-03
JP2838147B2 (ja) 1998-12-16
PT92187B (pt) 1995-06-30
CA2002218C (fr) 2000-08-08
IE76312B1 (en) 1997-10-22
EP0368131A3 (en) 1990-12-19
EP0368131B1 (fr) 1996-09-04
JPH02173000A (ja) 1990-07-04

Similar Documents

Publication Publication Date Title
AU5772886A (en) Novel procoagulant proteins
EP0759067A4 (fr) Facteur transformant de croissance alpha h1
NO884154D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive preparater.
FI104255B1 (fi) Menetelmä ihmisen seerumialbumiinin N-terminaalifragmentteja sisältävien fuusioproteiinien valmistamiseksi
AU1130392A (en) Synthetic htlv-iii peptides, compositions and uses thereof
EP0345549A3 (en) Removal of protein a from antibody preparations
AU3125289A (en) Monoclonal antibodies directed against human tumor necrosis factor - receptor
CA2098021A1 (fr) Composition utilisee comme agent therapeutique contre les hepatopathies virales chroniques
CA2149770A1 (fr) Detection de l'hypoxie
AU624436B2 (en) Albumin preparation and process for preparing the same
AU3937289A (en) Hybrid protein c constructs and methods for their preparation
CA2002218A1 (fr) Neoglycoproteines, preparation et utilisation
EP0227619A3 (fr) Protéine et son application
GR3015890T3 (en) Novel peptides, their use as immuno suppressants and processes for their preparation.
CA2139518A1 (fr) Regions antigeniques des complexes de particules liberes par les tumeurs et anticorps
FR2635115B1 (fr) Procede de preparation de la serum albumine humaine a partir d'une levure
EP0209284A3 (fr) Dérivés de l'anthraquinone
AU592023B2 (en) Synthetic peptide compounds producing antibodies binding to human ldh-c4
AU7633987A (en) The use of 15-deoxyspergualine as a pharmaceutical
EP0213595A3 (fr) Transferrines et leur application
EP0662150A4 (fr) Maspin, nouveau serpin a activite antitumorale.
AU5752490A (en) A novel tumor associated antigen
AU7422387A (en) Tumor necrosis factor alpha as treatment for infectious diseases
AU4668889A (en) Monoclonal antibodies specific for tumor antigens
AU5954990A (en) Production of antigens by self-assembly of polypeptide components

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed